Select a Region North America


Lee Ann Steadman



Consulting (Strategy Management & Regulatory), Market Access, Oncology, Specialty & Direct-to-Patient Distribution

Lee Ann brings with her more than 15 years of pharmaceutical and medical device experience working with companies such as Sanofi, Lash Group and UBC, Inc. Lee Ann uses her expertise to support the full life cycle of a product.​​

With her knowledge in patient and provider services and channel strategy, Lee Ann has launched more than 30 patient and provider support programs including reimbursement, distribution, financial assistance programs, call centers, sites of care and clinical trial support services across numerous therapeutic classes. Her experience includes support of oncology, rheumatology, neurology, cardiology and rare diseases.​​

Lee Ann earned a BS degree in Psychology and minor in Business from Kansas State University.

Articles by Lee Ann Steadman

Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling

In the fast-paced world of pharmaceuticals, where market forecasting and regulatory compliance are paramount, data-driven insights can make all the difference. Discover how EVERSANA’s Specialty Consulting team excels in crafting tailored predictive modeling solutions for pharmaceutical manufacturers of all sizes. With a comprehensive understanding of the challenges inherent in product commercialization, we offer strategic advantages […]

Maximizing Product Launch Success: The Importance of Conducting Comprehensive Business Simulation Exercises

Product launch preparedness is a vital aspect of bringing new products to market, particularly in the pharmaceutical industry where patients’ health and well-being can be impacted, in addition to the brand’s success and overall reputation. As 66% of new products fail to meet launch expectations, it is important for manufacturers to prioritize pre-launch preparedness and […]

Left-Right-Left: The Latest in Pharma-Payer Ping Pong

Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have a long history of one-upmanship. Are pharma motivations for offering copay assistance centered on the patient, their own bottom […]

Solving the Wastage Challenge Through Predictive Analytics and Modeling

“Solving the Wastage Challenge Through Predictive Analytics and Modeling,” authored by John Chatas, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores how legislative changes like the Wastage Reduction Act are driving pharma companies to find innovative ways to minimize product wastage & avoid costly fines. EVERSANA’s #SpecialtyConsulting supports […]

FRM Satisfaction Survey POV
Elevating Field Reimbursement Manager Performance through Insights & Comparative Data

“Elevating Field Reimbursement Managers’ Performance through Customer-based Insights and Comparative Data,” authored by David Frey, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores the evolving role of Field Reimbursement Managers (FRMs) and how it has evolved to become a critical role for pharmaceutical manufacturers. This article also reviews […]

Commercialization Strategies in Oncology — The Right Partner Can Reduce Risk and Boost Rewards

Whether you are an emerging company launching your first product or an established company expanding your portfolio, a number of parallel initiatives must be developed and executed to help your therapy get out of the shadow zone and into the limelight. Working closely with the right partner can help your company to differentiate the therapy, […]

THINK BEYOND THE THERAPY: Demystifying the Complexities of Cell and Gene Therapy Commercialization

While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical trial or product launch, even the best-planned efforts can be derailed without a clear strategy for facilitating access to […]

Are You Tracking the Performance and Satisfaction Ratings of Your Patient Services?

The types of services patients need for support change and fluctuate over time, particularly as a product moves through its lifecycle. The patient services necessary to drive access, affordability and adherence to your product in the launch phase can be markedly different from the patient services that accomplish the same goals at later stages of […]

Optimizing the Performance of a PSP and Improving Outcomes For All Stakeholders

Patient Support Programs (PSP) have been proven to improve clinical and patient outcomes and help manage patient out-of-pocket cost and prescribed use. Particularly for specialty drugs, the services provided under the PSP umbrella not only help remove barriers to patient access, they provide healthcare providers (HCPs) with tools they can use to help patients better […]

Interested in scheduling a meeting or speaking event?